DK3182980T3 - Behandling af glykosyleringsmangelsygdomme - Google Patents
Behandling af glykosyleringsmangelsygdomme Download PDFInfo
- Publication number
- DK3182980T3 DK3182980T3 DK15833822.8T DK15833822T DK3182980T3 DK 3182980 T3 DK3182980 T3 DK 3182980T3 DK 15833822 T DK15833822 T DK 15833822T DK 3182980 T3 DK3182980 T3 DK 3182980T3
- Authority
- DK
- Denmark
- Prior art keywords
- glycosyling
- treatment
- deficiency diseases
- deficiency
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462039052P | 2014-08-19 | 2014-08-19 | |
PCT/US2015/045896 WO2016028894A1 (en) | 2014-08-19 | 2015-08-19 | Treatment of glycosylation deficiency diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3182980T3 true DK3182980T3 (da) | 2021-01-11 |
Family
ID=55351228
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15833822.8T DK3182980T3 (da) | 2014-08-19 | 2015-08-19 | Behandling af glykosyleringsmangelsygdomme |
Country Status (6)
Country | Link |
---|---|
US (2) | US20170209476A1 (da) |
EP (1) | EP3182980B1 (da) |
DK (1) | DK3182980T3 (da) |
ES (1) | ES2841745T3 (da) |
PL (1) | PL3182980T3 (da) |
WO (1) | WO2016028894A1 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210187001A1 (en) * | 2018-02-01 | 2021-06-24 | Wellstat Therapeutics Corporation | Compositions and Devices for Systemic Delivery of Uridine |
AU2019285303A1 (en) * | 2018-06-14 | 2020-12-17 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Methods and materials for treating glycosylation disorders |
MX2023002868A (es) * | 2020-09-14 | 2023-03-24 | Wellstat Therapeutics Corp | 2',3'-diacetiluridina sustituida por acetoacetilo en la posicion 5'. |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL144964A0 (en) * | 1999-02-23 | 2002-06-30 | Pro Neuron Inc | Methods of treatment of mitochondrial disorders |
WO2007064691A1 (en) * | 2005-12-02 | 2007-06-07 | Nabil Habib Lab | Treatment of cancer and other diseases |
US20120078529A1 (en) * | 2009-05-13 | 2012-03-29 | Wellstat Therapeutics Corporation | Determining the severity of 5-fluorouracil overdose |
US20110257233A1 (en) * | 2010-03-19 | 2011-10-20 | Sanford-Burnham Medical Research Institute | Benzoisothiazolones as inhibitors of phosphomannose isomerase |
US20150045416A1 (en) * | 2012-01-05 | 2015-02-12 | Hadasit Medical Research Services & Development Ltd. | Methods and Compositions for Gene Delivery |
-
2015
- 2015-08-19 DK DK15833822.8T patent/DK3182980T3/da active
- 2015-08-19 ES ES15833822T patent/ES2841745T3/es active Active
- 2015-08-19 PL PL15833822T patent/PL3182980T3/pl unknown
- 2015-08-19 EP EP15833822.8A patent/EP3182980B1/en not_active Not-in-force
- 2015-08-19 WO PCT/US2015/045896 patent/WO2016028894A1/en active Application Filing
- 2015-08-19 US US15/329,647 patent/US20170209476A1/en active Pending
-
2022
- 2022-02-09 US US17/667,703 patent/US20220273688A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220273688A1 (en) | 2022-09-01 |
EP3182980A1 (en) | 2017-06-28 |
EP3182980B1 (en) | 2020-10-14 |
EP3182980A4 (en) | 2018-06-06 |
PL3182980T3 (pl) | 2021-04-19 |
ES2841745T3 (es) | 2021-07-09 |
WO2016028894A1 (en) | 2016-02-25 |
US20170209476A1 (en) | 2017-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3134530T3 (da) | Behandling af hyperbilirubinæmi | |
DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
DK3450553T3 (da) | Mrna-terapi til behandling af øjensygdomme | |
DK3171928T3 (da) | Stimulationsmønstre til behandling af tørt øje | |
DK3125875T3 (da) | Inhalerbar rapamycinformulering til behandling af aldersrelaterede tilstande | |
DK3169328T3 (da) | Quinolinderivater til behandling af inflammationssygdomme | |
DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
DK3231444T3 (da) | Ny behandling | |
DK3307267T3 (da) | Behandling af multipel sklerose | |
DK3132009T3 (da) | Fremgangsmåde | |
DK3283210T3 (da) | Fremgangsmåde | |
DK3237621T3 (da) | Varianter af human alpha-galactosidase | |
DK3166628T3 (da) | Terapeutisk anvendelse af knoglemorfogenetiske proteiner | |
DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
DK3164123T3 (da) | Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier | |
DK3097085T3 (da) | Benzoxazinonderivater til behandling af hudsygdomme | |
DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
DK3151814T3 (da) | Behandling af en hudlæsion | |
DK2897382T3 (da) | Forbedring af binaural kilde | |
DK3374495T3 (da) | Forbedrede fremgangsmåder til vævsfremstilling | |
DK3848028T3 (da) | Fremgangsmåder til behandling af øjenlidelser | |
DK3096775T3 (da) | SOCS-mimetika til behandling af sygdomme |